Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy

Trial ID or NCT#

NCT01479478

Status

not recruiting iconNOT RECRUITING

Purpose

The investigators wish to determine if oral probiotic supplementation during the second half of pregnancy decreases maternal GBS recto-vaginal colonization at 35-37 weeks' gestational age, thereby decreasing need for maternal antibiotic administration at time of labor. The importance of this study is that it may offer a safer alternative to antibiotic treatment of group B Streptococcus (GBS) colonized pregnant women.

Official Title

Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.

Eligibility Criteria

Ages Eligible for Study: 18 Years to 55 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. 1. Pregnant women between 20-28 weeks gestation. 2. 18 years of age or older. 3. Singleton gestation.
Exclusion Criteria:
  1. 1. Preexisting morbidity: Immunocompromised status (HIV +; malignancy; history of organ transplant; chronic steroid therapy; autoimmune disease requiring treatment during pregnancy, and other immunocompromised states); Type 1 diabetes and type 2 diabetes;congenital cardiac disease and cardiac valvular disease requiring antibiotic prophylaxis during procedure/labor; pulmonary disease (except mild asthma); renal disease; chronic hepatic disease (Hepatitis B, C); inflammatory bowel disease (Crohn's disease or ulcerative colitis); stomach or duodenal ulcer; bowel resection, gastric bypass, and chronic indwelling venous, bladder, or gastric catheter. 2. Multi-fetal gestation. 3. Use of probiotics preparations in the 3 months prior to beginning of the study treatment or use of any additional probiotics preparations (other than study treatment) at any time during the study period (including over the counter food supplements such as Activia, BioK, other oral or vaginal probiotics products (BUT not including other common forms of yogurt). 4. Chronic (daily) use of broad spectrum antibiotics. 5. History of infant with GBS sepsis. 6. Intrauterine Growth Restriction (IUGR), Fetal Anomalies-major diagnosed at time of second trimester anatomy ultrasound 7. Anticipated delivery <35 wks for maternal/fetal indication 8. Placenta previa or accreta (with anticipated delivery prior to 35 weeks)

Investigator(s)

Natali Aziz, M.D., M.S.
Natali Aziz, M.D., M.S.
Obstetrician and Gynecologist (OB-GYN)
Clinical Associate Professor, Obstetrics & Gynecology - Maternal Fetal Medicine

Contact us to find out if this trial is right for you.

Contact

Cynthia Willson, RN
650-724-6372